Pelabresib anhydrous

Generic Name
Pelabresib anhydrous
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H16ClN3O2
CAS Number
1380087-89-7
Unique Ingredient Identifier
U4017GUQ06
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

First Posted Date
2024-05-06
Last Posted Date
2024-12-17
Lead Sponsor
Constellation Pharmaceuticals
Target Recruit Count
50
Registration Number
NCT06401356
Locations
🇺🇸

Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology), Los Angeles, California, United States

🇺🇸

Mayo Clinic (Cancer Clinical Research Office), Jacksonville, Florida, United States

🇺🇸

Northwestern Memorial Hospital (Oncology), Chicago, Illinois, United States

and more 12 locations

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

First Posted Date
2022-05-25
Last Posted Date
2024-03-05
Lead Sponsor
Constellation Pharmaceuticals
Target Recruit Count
35
Registration Number
NCT05391022
Locations
🇬🇪

Simon Khechinashvili University Hospital, Tbilisi, Georgia

🇬🇪

K. Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia

🇪🇸

Hospital Universitario Virgen del Rocío, Sevilla, Spain

and more 7 locations

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

First Posted Date
2020-10-26
Last Posted Date
2024-10-28
Lead Sponsor
Constellation Pharmaceuticals
Target Recruit Count
430
Registration Number
NCT04603495
Locations
🇺🇸

Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL, Decatur, Illinois, United States

🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

🇲🇾

Sunway Medical Centre, Petaling Jaya, Selangor, Malaysia

and more 153 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy